Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dienogenance
- Development stage
- Phase 4
- Lead developer
- Mibe Arzneimittel
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dienogenance is an approved combined oral contraceptive (film-coated tablet) developed and manufactured by Mibe Arzneimittel. It is a generic version of Valette, containing a fixed-dose combination of the progestogen dienogest (2.0 mg) and the estrogen ethinylestradiol (0.03 mg). Dienogenance is indicated for female contraception and the treatment of moderate acne in women who have no contraindications to oral contraceptives and in whom suitable topical or antibiotic treatments have failed. Dienogest acts as an agonist at the progesterone receptor and an antagonist at the androgen receptor, providing antiandrogenic activity that helps improve acne symptoms. Ethinylestradiol acts as an agonist at estrogen receptors, contributing to the inhibition of ovulation and alteration of cervical mucus to prevent pregnancy.
- Brand names
- DienogenanceDienogenance 2.0/0.03 mg
- Other names
- Dienogancedienogest + ethinylestradiol
02
Targets
AR (Adrenergic receptors)ESR1 (ERα)ESR2 (ERβ)PR (Progesterone receptor)
Beyond the preview
Go deeper on Dienogenance.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dienogenance.